Children's Medical Center Corporation

Luise Erpenbeck

Denisa D Wagner

Siu Ling Wong

Jörn Thilo Witsch

Alexander Savchenko

Kimberly Lindsay Martinod

Embodiments of the technology described herein are based, in part, upon the discovery that NETosis, the formation of neutrophil extracellular traps (NETs) is increased in wounds, in organ fibrosis and in subjects with diabetes. Accordingly, methods for treating wounds, fibrosis and NET associated complications in diabetes are provided. The methods comprise administrating a therapeutically effective amount of at least one anti-NET compound to a subject in need of treatment, e.g. a PAD 4 inhibitor, a DNase, a histone-degrading enzyme; an inhibitor of chromatin decondensation; an antibody against a component of a NET; an inhibitor of NET release, a protease inhibitor, or an elastase inhibitor.

Anti-NET compounds for treating and preventing fibrosis and for facilitating wound healing

Described herein are methods, assays, and compositions relating to the treatment of thrombosis, preeclampsia, cancer, and intestinal inflammation, e.g., by administering ADAMTS13 to a subject in need of treatment.

Growing community of inventors

Göttingen, Germany

Luise Erpenbeck